Actionnariat et activité des initiés pour Adaptimmune Therapeutics plc (ADAP): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $0.05 |
| Capitalisation | $75M |
| Bourse | NASDAQ |
| Pays | GB |
Bilan (10 ans)
| Année | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $229.1M | $158.8M | $84.0M | $68.4M | $50.4M | $56.9M | $149.9M | $108.0M | $144.0M | $91.1M |
| Placements à Court Terme | $55.3M | $22.7M | $124.2M | $136.8M | $39.1M | $311.3M | $219.6M | $96.6M | $2.9M | $60.5M |
| Créances | $5.4M | $7.7M | $11.7M | $16.7M | $19.3M | $20.7M | $34.0M | $38.1M | $46.9M | $16.0M |
| Stocks | $102212 | $1.2M | $3.8M | $1.1M | $1.5M | 0 | 0 | 0 | 0 | $7.3M |
| Actifs Courants | $295.1M | $198.8M | $230.2M | $231.1M | $120.5M | $398.2M | $415.5M | $255.4M | $207.6M | $188.2M |
| Immobilisations Corporelles | $5.4M | $27.9M | $40.7M | $36.1M | $51.9M | $46.7M | $51.4M | $71.5M | $71.7M | $51.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | $177692 | $1.3M | $1.3M | $1.5M | $2.2M | $1.7M | $1.0M | $442000 | $330000 | $3.9M |
| Actifs Totaux | $300.7M | $234.5M | $281.1M | $276.7M | $181.5M | $451.1M | $469.5M | $328.9M | $282.6M | $246.0M |
| Dettes Fournisseurs | $7.8M | $11.3M | $8.4M | $4.1M | $6.4M | $6.4M | $8.1M | $4.8M | $8.1M | $8.7M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $26.8M | $40.3M | $74.3M | $24.4M | $34.3M | $39.1M | $62.5M | $64.5M | $72.8M | $64.5M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $50.2M |
| Passifs Totaux | $41.1M | $68.4M | $78.2M | $29.9M | $57.9M | $109.9M | $263.6M | $247.0M | $243.1M | $234.1M |
| Réserves | -$47.2M | -$161.5M | -$231.6M | -$318.5M | -$455.7M | -$585.8M | -$743.8M | -$909.3M | -$1.02B | -$1.09B |
| Capitaux Propres | $259.6M | $166.1M | $203.0M | $246.9M | $123.6M | $341.2M | $206.0M | $81.9M | $39.5M | $11.8M |
| Dette Totale | 0 | 0 | $124.2M | $136.8M | $25.5M | $23.7M | $25.5M | $23.1M | $25.2M | $74.2M |
| Dette Nette | -$284.4M | -$181.5M | -$84.0M | -$68.4M | -$64.1M | -$344.5M | -$344.1M | -$181.5M | -$121.7M | -$77.4M |
| Fonds de Roulement | $268.3M | $158.5M | $155.9M | $206.7M | $86.1M | $359.1M | $352.9M | $190.9M | $134.8M | $123.6M |
Santé financière
| Dette / Capitaux propres | -0.69 |
| Ratio de liquidité | 1.52 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -5.47 |
Rentabilité
| Rentabilité des capitaux propres | 143.79% |
| Rentabilité du capital investi | -90.90% |
| Rentabilité des actifs | -59.65% |
| Marge brute | 83.88% |
| Marge opérationnelle | -362.66% |
| Marge nette | -371.74% |
Entreprises liées: ANL · APLM · BLRX · ERNA · GOVX · LNAI · LPCN
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ADAP: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions